WCLC News
-
TROPION-Lung01 Demonstrates Improvement in PFS; OS Improvement Fails to Reach Statistical Significance
Dr. Jacob Sands presented findings that show a progression-free survival advantage for Dato-DXd versus docetaxel in the non-squamous cohort.
-
Climate Change, Pollution, War, and More Increasing Risk, Impacting Management of Lung Cancer Worldwide
Dr. Leticia Nogueira and other experts explored non-tobacco factors that are playing a role in our evolving knowledge during a WCLC 24 plenary session.
-
Artificial Intelligence-Powered Tools May Help Develop Predictive Biomarkers
Dr. Kenneth O’Byrne says research shows novel method for analyzing tissue samples may help predict immunotherapy response.
-
Interim Analysis Shows IDeate-Lung01 Study Met Primary Endpoint
Dr. Charles Rudin says early data look promising for I-DXd in patients with ES-SCLC.
-
Hands-On Genomics Workshop Enables Participants to Integrate Genomic Testing Into Patient Care
Drs. Ramaswamy Govindan, Richard Haspel, and Aparna Sharma took the audience on a guided tour of pragmatic lung cancer genomics.
-
Save the Date: Planning Begins for the 2025 World Conference on Lung Cancer
Drs. Isabelle Opitz, Umberto Malapelle, Noemi Reguart, and Jarushka Naidoo will co-chair the event, which will return to Barcelona next September.
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
During the session, Dr. Hisao Asamura reviewed the criteria changes in the new 9th edition of the TNM classification recommendations.
-
Novel, Targeted TKI Brings Hope to a Rare, Clinically Challenging Disease
Dr. Gerrina Ruiter says zongertinib shows encouraging preliminary findings in patients with HER2-mutated NSCLC.
-
Study Results Support Continued Research of HER2-Targeted TKI
Dr. Xiuning Le presented data from a first-in-human trial that show a rapid, durable response in HER2-mutated NSCLC.
-
Study Shows AI-Based Method Predicts Gene Mutation, Distribution in a More Timely, Accurate, and Economical Way Compared to NGS
Dr. Shan Xiong says the technology achieved robust and superior predictive performance across cancer genes of diverse types and across racial backgrounds.
View ILCN Archives
Provider Resources